Format

Send to

Choose Destination
CMAJ Open. 2020 Jan 28;8(1):E41-E47. doi: 10.9778/cmajo.20190105. Print 2020 Jan-Mar.

Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey.

Author information

1
Faculty of Medicine (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Université de Montréal; Centre de recherche de l'Hôpital du Sacré-Coeur de Montréal (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Montréal, Que.; Département de médecine sociale et preventive (Guertin), Faculty of Medicine, Université Laval; Centre de recherche du Centre hospitalier universitaire de Québec (Guertin), Québec, Que.
2
Faculty of Medicine (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Université de Montréal; Centre de recherche de l'Hôpital du Sacré-Coeur de Montréal (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Montréal, Que.; Département de médecine sociale et preventive (Guertin), Faculty of Medicine, Université Laval; Centre de recherche du Centre hospitalier universitaire de Québec (Guertin), Québec, Que. f.madore@umontreal.ca.

Abstract

BACKGROUND:

The debate over acetylsalicylic acid (ASA) therapy for primary prevention of cardiovascular disease (CVD) has recently resurfaced, but scarce data are available on prophylactic ASA use in Canada for this purpose. This study aimed to evaluate the prevalence and factors associated with ASA use, and the potential impact of implementing the most recent (2016) US Preventive Services Task Force recommendations for primary CVD prevention in a Canadian setting.

METHODS:

We performed a cross-sectional analysis using data from the CARTaGENE study, which included a representative sample (n = 20 004) of the 2018 general population of the province of Quebec. We assessed eligibility for ASA treatment using US Preventive Services Task Force criteria (age 50-69 yr, no past history of myocardial infarction or stroke, and 10-year risk of CVD of at least 10%). We extrapolated to the entire 2018 Quebec population the number of people who would need to start ASA treatment.

RESULTS:

A total of 6231 respondents in the CARTaGENE study (54.2% of those aged 50-69 yr with no prior history of CVD) were found to be potentially eligible for ASA use for primary CVD prevention. Of the 6231, 1379 (22.1%) were receiving prophylactic ASA treatment. Factors found to be related to ASA use included age, male sex, regular medical visits, lower education level, obesity, hypertension, diabetes and dyslipidemia. Income and smoking status were not found to be significantly associated with ASA use. Our results indicate that 885 261 people would potentially have started ASA treatment if the US Preventive Services Task Force recommendations had been implemented in Quebec in 2018.

INTERPRETATION:

Prevalent ASA use for primary CVD prevention was low. Implementation of the 2016 US Preventive Services Task Force recommendations would require initiating ASA treatment in a substantial proportion of people, with undetermined potential benefits.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center